****

For retirees seeking reliable income through dividend stocks, Pfizer and Verizon Communications stand out as robust choices that offer high yields exceeding 6%. Despite hurdles in their respective sectors, both companies demonstrate strong fundamentals that mitigate investment risks commonly linked with high-yield stocks.

Pfizer, a distinguished player in the healthcare industry, is currently grappling with some challenges. The company’s stock has dipped over 10% this year, largely due to a bearish sentiment about its future prospects. Despite these concerns, Pfizer’s dividend yield stands impressively at around 6.8% as it trades near its 52-week low. CEO Albert Bourla has emphasized the "sacred" nature of maintaining these dividends, reinforcing the company’s commitment to shareholder returns. With a record of 344 consecutive quarterly dividend payments, Pfizer has proven to be a stable income source in the healthcare sector.

The company's forward-looking strategy is equally reassuring. Pfizer has recently lifted its 2024 guidance, buoyed by robust earnings. Still, questions linger about its adaptation to potential regulatory changes under a new U.S. administration and impending patent expirations on key drugs. To counteract these issues, Pfizer is aggressively pushing for innovation and growth. Among its notable moves is the $43 billion acquisition of oncology firm Seagen last year. Future projections indicate that by 2030, new drugs and acquisitions could add up to $25 billion in revenue, effectively offsetting the expected losses from generic competition.

Verizon Communications also presents a compelling case for retirees. The telecom giant offers a 6.5% yield and has been consistently increasing its dividend for 18 consecutive years, including a 1.9% hike in September. Although Verizon’s growth in its core wireless service is projected between 2% and 3.5% this year, the company’s strategic initiatives could spur future expansion. The planned $20 billion acquisition of Frontier Communications is set to enhance Verizon’s fiber network, with the deal anticipated to close in early 2026.

Verizon's stock, though, has faced investor skepticism amid rising interest rates that typically weigh down capital-intensive businesses. Yet, as financial conditions evolve, the stock’s outlook may improve. Priced at less than 9 times its expected earnings for the next year, Verizon remains an attractive, undervalued proposition for investors seeking safe, high-yield returns.

These attributes make Pfizer and Verizon solid long-term investments for retirees, offering both high dividends and strategic growth potential.